Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C Pola R-CHP+X vs CR-CHOP in Previously Untreated DEL
NCT07511114Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07511114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511114.